BTIG downgrades Accuray stock rating on revenue challenges and guidance withdrawal
BTIG has downgraded Accuray (NASDAQ:ARAY) from Buy to Neutral and removed its price target due to ongoing revenue challenges and the withdrawal of financial guidance. The company’s stock has fallen 59% in six months, and despite cost-cutting efforts, product revenue is constrained by geopolitical uncertainty and adjusted EBITDA missed expectations. Accuray, which remains unprofitable, also reported an earnings per share miss and lower-than-anticipated revenue for its fiscal third quarter 2026.
Price to book forward of Accuray Incorporated – NASDAQ:ARAY
This article provides financial data specifically on the "Price to book forward" for Accuray Incorporated (NASDAQ: ARAY). It is part of the financials section on TradingView, focusing on the company's valuation metric for investors. The content presents a snapshot of this financial ratio, indicating its period, value, and change.
Accuray Incorporated Actuals & Estimates (NASDAQ:ARAY)
Accuray Incorporated (NASDAQ: ARAY) stock has seen significant declines recently, with a −25.18% drop in the past week and an −80.47% decrease over the last year. Analysts provide a mixed forecast, with a maximum and minimum price estimate of $0.35. The company's next earnings report is due on August 19, 2026, following a negative surprise in the last quarter's earnings and revenue figures.
Accuray (ARAY) Stock Sees Fair Value Cut After Downgrades And Lower Growth Assumptions
Accuray (ARAY) has seen its fair value estimate drastically cut from US$3.88 to US$0.35 following downgrades from Jefferies and BTIG. Analysts are adopting more cautious assumptions, leading to lower price targets and a more conservative outlook on the stock. This revision reflects concerns over execution, growth prospects, and changes in revenue growth assumptions and net profit margin expectations.
Enterprise value to revenue forward of Accuray Incorporated – LSE:0H8I
This article provides financial information for Accuray Incorporated (LSE: 0H8I), specifically focusing on its enterprise value to revenue forward. It displays the company's financial overview within the TradingView platform, noting the market is currently closed.
Accuray Incorporated Actuals & Estimates (BX:XEJ)
This article provides an overview of Accuray Incorporated (XEJ) financials, including stock price, market capitalization, earnings, and revenue. It covers analyst forecasts, historical price data, and upcoming earnings dates, offering a comprehensive financial snapshot for potential investors.
Enterprise value to EBIT forward of Accuray Incorporated – LSE:0H8I
This article displays the "Enterprise value to EBIT forward" metric for Accuray Incorporated (LSE:0H8I) on TradingView. It shows that there are no current trades for the stock, indicating the market is closed. The content focuses solely on this financial data point for the specified company.
Accuray Incorporated Actuals & Estimates (MUN:XEJ)
This article provides financial actuals and estimates for Accuray Incorporated (XEJ) traded on the Munich Stock Exchange. It covers income statement, balance sheet, cash flow data, and valuation metrics, comparing actual results with analyst estimates. The piece also addresses frequently asked questions about the company's stock, including forecasts, historical prices, earnings reports, revenue, net income, dividends, employee count, and EBITDA.
Enterprise value to EBIT forward of Accuray Incorporated – NASDAQ:ARAY
This article provides financial information for Accuray Incorporated (NASDAQ: ARAY), specifically focusing on its enterprise value to EBIT forward. It indicates a period value and changes in that value for the company. The financial data is sourced from ICE Data Services and FactSet Research Systems Inc.
Enterprise value to EBITDA forward of Accuray Incorporated – NASDAQ:ARAY
This article displays the "Enterprise value to EBITDA forward" financial metric for Accuray Incorporated (NASDAQ: ARAY). The page indicates that the market was closed and no trades occurred. It appears to be a financial data point from TradingView, which provides market and financial information.
Accuray Inc (ARAY) Valuation: PE, PB & Fair Value Analysis
Accuray Inc (ARAY) currently has a valuation score of 9.07, ranking 45th out of 203 companies in the Healthcare Equipment & Supplies industry. The company's P/E ratio stands at -0.84, which is significantly below its recent high and above its recent low. Key valuation metrics like P/E, P/B, P/S, and P/CF show that relevant data have not been disclosed by the company yet, suggesting a lack of comprehensive valuation information.
Accuray Inc (ARAY) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Accuray Inc (ARAY), outlining its current price momentum, support and resistance levels, and the status of various technical indicators and moving averages. The analysis suggests that ARAY is suitable for range-bound swing trading, with its stock price fluctuating between a resistance level of 0.43 and a support level of 0.29. Based on technical indicators and moving averages, the overall signal for Accuray Inc is currently a "Sell".
Accuray Inc (ARAY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed breakdown of Accuray Inc (ARAY)'s revenue by business segment and geographical region, updated as of April 6. The company's revenue is primarily generated from Service (55.98%) and Product (44.02%) segments. Geographically, Europe, Middle East, India, and Africa contribute the most (42.40%), followed by Asia Pacific (excluding Japan and China), Americas, China, and Japan.
Accuray Inc (ARAY) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Accuray Inc (ARAY) focused on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and shows no record of stock splits. The page also includes current stock price data for ARAY.
Accuray Inc (ARAY) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Accuray Inc (ARAY), highlighting its current earnings forecast score, average price target from analysts, and peer comparison. It details expected revenue for the next quarter, historical and forecasted EPS, and concludes with an overall "Hold" rating from analysts.
[144] ACCURAY INC SEC Filing
This SEC filing (Form 144) for Accuray Inc. (ARAY) details a proposed sale of securities. The document outlines the filer information, issuer information, and specifics about the securities to be sold, including the class of securities, number of units, and aggregate market value, with a proposed sale date of June 12, 2026. The filing indicates a neutral impact and sentiment.
Accuray Company Profile & Introduction
This document appears to be a placeholder or incomplete article about Accuray, a company in the medical device sector. It likely intends to provide a profile and introduction to the company's operations, products, or financial standing. However, the content currently provided is empty.
ARAY News | ACCURAY INC (NASDAQ:ARAY)
This article provides recent news and analysis for Accuray Inc (NASDAQ: ARAY), including stock performance and links to press releases. Key updates highlight the company's financial results, recent business developments, and a notice regarding an inducement award.
Accuray (NASDAQ: ARAY) fully repays $18M 3.75% notes at maturity
Accuray Incorporated (NASDAQ: ARAY) has fully repaid its $18 million 3.75% Convertible Senior Notes due 2026 at maturity. The company paid the remaining principal and $337,500 in accrued interest on June 1, 2026, satisfying and discharging the related Indenture. This action simplifies Accuray's debt structure and releases it from associated obligations, with the event classified as a moderate filing impact and neutral sentiment.
Earnings call transcript: Accuray’s Q3 2026 results miss forecasts, shares drop
Accuray reported a significant miss in its fiscal Q3 2026 earnings, posting an EPS of -$0.09 against a forecasted -$0.02, and revenue of $104.8 million against an anticipated $111.9 million. The company's stock dropped 2.39% in aftermarket trading, reflecting investor concerns over macroeconomic headwinds, geopolitical tensions, and the subsequent withdrawal of its fiscal 2026 guidance. Despite these challenges, Accuray is implementing a transformation plan focused on innovation, cost control, and strategic partnerships to drive future growth and improve financial performance by fiscal years 2027 and 2028.
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
Accuray Incorporated announced an inducement award granted to new employee Paul Krauss, consisting of 200,000 restricted stock units. This award, made under NASDAQ Listing Rule 5635(c)(4), will vest over four years based on continuous employment and is separate from the company's 2022 Equity Incentive Plan.
Accuray (NASDAQ: ARAY) grants SVP Paul Miele 650,000 restricted stock units
Accuray (NASDAQ: ARAY) has granted its Senior Vice President and Chief Commercial Officer, Paul Michael Miele, 650,000 restricted stock units (RSUs). These RSUs represent a contingent right to receive one share of common stock each and are an equity-based compensation award designed to align Miele's compensation with the company's long-term share performance. The RSUs will vest in quarterly installments, with the first portion vesting on April 30, 2027, and subsequent portions vesting on the first, second, and third anniversaries of that date.
Accuray Incorporated Reports Inducement Award Under Nasdaq Listing Rules
Accuray Incorporated has reported an inducement award as required by Nasdaq Listing Rules. The article, provided by Refinitiv and distributed via Reuters, states this information succinctly. Further details are contingent on logging in or creating an account.
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
Accuray Incorporated has reported inducement awards to its new Chief Commercial Officer, Paul Miele, and new Chief Legal Officer, David Shin, as required by NASDAQ Listing Rules. These equity awards, comprised of restricted stock units (RSUs) and performance-based restricted stock units (PSUs), were granted to incentivize them to join the company. The awards are subject to vesting schedules and performance criteria, aligning with the company's existing equity incentive plan terms.
ARAY - Accuray Inc Stock Price and Quote
This page provides a detailed financial overview of Accuray Inc (ARAY), including its current stock price, key financial metrics, insider transactions, and a history of analyst ratings. It also lists recent news articles and press releases related to the company's activities, such as inducement awards, research agreements, and financial results.
Accuray stock tumbles after earnings miss, guidance withdrawal
Accuray stock fell following an earnings miss and withdrawal of guidance. The company reported a Q4 loss and lower than expected revenue, impacting investor confidence.
Accuray(ARAY) Stock Options Chain | Quotes & News
This article provides the stock options chain, quotes, and news for Accuray (ARAY). It serves as a resource for investors interested in the company's financial data and latest updates.
TCW Group boosts Accuray (ARAY) stake to 13.7% through loan-linked warrants
The TCW Group, Inc. has increased its beneficial ownership in Accuray Incorporated (ARAY) to approximately 13.7% through warrants linked to a Delayed Draw Term Loan. This stake, totaling 18,942,059 shares, includes common stock purchase warrants exercisable at various prices and terms running until May 19, 2033. The warrants were issued as a condition for TCW to provide financing to Accuray, with no separate consideration paid for them.
TCW Group (NASDAQ: ARAY) affiliates receive Accuray warrants tied to term loan
Affiliates of TCW Group received warrants to purchase 18,942,059 shares of Accuray common stock as part of a financing agreement. These warrants, with exercise prices ranging from $0.01 to $1.50 per share and expiring in May 2033, were issued as consideration for a Delayed Draw Term Loan. This transaction, classified as a restructuring-related entry (code J), clarifies institutional warrant holdings rather than open-market trading.
Radiotherapy Market Key Players | Siemens Healthineers AG, Accuray Incorporated, Elekta AB etc.
The global radiotherapy market is projected to reach US$ 10,170.80 million by 2028, growing at a CAGR of 5.9% from 2021 to 2028, driven by the increasing global cancer burden and technological advancements. The market is undergoing transformation due to precision oncology, AI, and advanced imaging, with key trends including precision radiotherapy, AI-driven planning, and expanding proton therapy. North America leads the market, while Asia-Pacific is expected to be the fastest-growing region.
Accuray brings AI in radiotherapy to ESTRO stage focusing on clinical performance and ethics
Accuray will present on the integration of artificial intelligence in radiotherapy at the ESTRO event, covering clinical performance, legal frameworks, and ethical considerations. The discussion aims to explore how AI can enhance patient care while addressing regulatory and ethical challenges. This follows Accuray's recent clinical success with its Radixact system in Myanmar and demonstrations of CyberKnife and helical platforms at previous conferences.
Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer – Company Announcement
Accuray and the University of Wisconsin School of Medicine and Public Health (UW SMPH) have announced a new 10-year strategic collaboration. This Master Research Agreement aims to advance personalized cancer treatments using Accuray's Stellar™ adaptive radiation therapy platform. The partnership builds on a long history of innovation, including the development of the TomoTherapy® System, and will focus on clinical research, education, training, and adaptive therapies.
10-year Accuray–UW alliance aims to tailor radiation for cancer patients
Accuray and the University of Wisconsin School of Medicine and Public Health have announced a 10-year Master Research Agreement to advance personalized cancer care using Accuray's Stellar adaptive radiation therapy platform. This collaboration will support clinical research, education, training, and the development of next-generation adaptive radiotherapy. The partnership builds on their history, which includes UW-invented technology commercialized as Accuray's TomoTherapy System.
News Flash: 2 Analysts Think Accuray Incorporated (NASDAQ:ARAY) Earnings Are Under Threat
This article highlights that two analysts are concerned about Accuray Incorporated's (NASDAQ:ARAY) upcoming earnings. These concerns are rooted in recent financial performance and market conditions, suggesting potential challenges for the company's profitability. Investors are advised to consider these analyst warnings as they evaluate their position in ARAY.
Accuray Shares Fall After Jefferies Downgrade
Accuray (ARAY) shares dropped following a downgrade from Jefferies. Analyst Michael Petusky downgraded the stock to Hold from Buy and reduced the price target significantly from $8.50 to $3.00, citing increased business risk. Petusky highlighted concerns about competition and Accuray's ability to compete effectively against larger firms while also noting potential downside risk for fiscal 2026 sales and earnings guidance.
Jefferies downgrades Accuray stock rating on guidance withdrawal By Investing.com
Jefferies downgraded Accuray Inc. (NASDAQ:ARAY) to Hold from Buy and cut its price target significantly, following the company's fiscal third-quarter miss and withdrawal of full-year guidance. Accuray cited geopolitical uncertainties in the Middle East causing shipment delays and ongoing issues with its China joint venture. Another firm, BTIG, also downgraded Accuray, highlighting persistent revenue challenges and the withdrawal of financial guidance for fiscal year 2026.
Accuray Slides As Insider Purchases Lose Another US$95k
Accuray Incorporated (NASDAQ:ARAY) insiders lost US$95k on their investments after a 17% stock drop, despite purchasing US$216.4k worth of stock at an average of US$0.68 over the past year. Director Steven Mayer recently bought US$135k worth of shares, indicating continued confidence, though overall insider ownership is relatively low at 4.8%. The company's recent losses warrant caution for potential investors.
Accuray Inc reports results for the quarter ended March 31 - Earnings Summary
Accuray Inc (ARAY) has reported its financial results for the quarter that ended on March 31. This earnings summary was provided by Refinitiv and Reuters. The article is a brief news update regarding the company's financial performance.
Accuray Incorporated (NASDAQ:ARAY) Q3 2026 Earnings Call Transcript
Accuray Incorporated (NASDAQ: ARAY) reported a Q3 2026 EPS of $-0.09, missing expectations of $-0.05. The company's total revenue was $105 million, down 7% year-over-year, primarily due to geopolitical disruptions in the Middle East and ongoing headwinds in China. Accuray withdrew its financial guidance due to significant unpredictability but remains confident in its transformation plan, which aims to improve operating profitability by approximately $25 million annually.
Accuray: Fiscal Q3 Earnings Snapshot
Accuray Inc. reported a fiscal third-quarter loss of $11.8 million, or 9 cents per share, on revenue of $104.8 million. The company's shares were trading at 49 cents on Wednesday, a decrease from $1.30 a year ago. This report was generated by Automated Insights using data from Zacks Investment Research.
Accuray Incorporated 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:ARAY) 2026-05-07
Accuray Incorporated (ARAY) has published its slide deck in conjunction with its 2026 Q3 earnings call presentation. This article by SA Transcripts highlights the availability of these materials for investors.
[8-K] ACCURAY INC Reports Material Event
Accuray Incorporated (NASDAQ: ARAY) reported weaker fiscal 2026 third-quarter results and withdrew its full-year guidance due to geopolitical uncertainty in the Middle East impacting installations. Total net revenue decreased by 7% to $104.8 million, and the net loss widened to $11.8 million, or $0.09 per share. Despite progress on a transformation plan, the company faces near-term visibility risks.
Accuray: Fiscal Q3 Earnings Snapshot
Accuray Inc. (ARAY) reported a fiscal third-quarter loss of $11.8 million, or 9 cents per share, on revenue of $104.8 million. The company's shares were trading at 49 cents at the close of Wednesday's trading, down from $1.30 a year ago. This financial summary was generated using data from Zacks Investment Research.
Accuray Inc expected to post a loss of 4 cents a share - Earnings Preview
Accuray Inc (ARAY) is expected to announce an earnings loss of 4 cents per share. This forecast is provided as an earnings preview by Refinitiv.
Accuray Incorporated Files Form 8-K Report with SEC Detailing Company Information and Compliance Data
Accuray Incorporated (NASDAQ: ARAY) announced the departure of its Senior Vice President and Chief Operations Officer, Leonel Peralta, effective April 26, 2026. The company specifically stated that the resignation was not due to any disagreements with the company's operations, policies, or board. This executive change was disclosed in a Form 8-K filing with the SEC, and shareholders are advised to monitor future disclosures regarding a new COO appointment.
Operations chief Leonel Peralta exits Accuray (NASDAQ: ARAY) leadership team
Accuray Incorporated announced that Leonel Peralta, Senior Vice President and Chief Operations Officer, departed the company effective April 26, 2026. The company stated that his resignation was not due to any disagreement with Accuray, its Board of Directors, or its operations, policies, or practices. The 8-K filing details this leadership change and includes standard exhibit information.
Accuray (ARAY) to Release Quarterly Earnings on Wednesday
Accuray (NASDAQ:ARAY) is scheduled to release its Q3 2026 earnings after market close on Wednesday, April 29th, with analysts projecting an EPS of ($0.05) and revenue of $111.90 million. In the previous quarter, the medical equipment provider met EPS estimates at ($0.11) and exceeded revenue expectations with $102.24 million, though it continues to operate at a loss. The stock, currently trading around $0.42 with a market cap of approximately $50 million, holds a consensus "Hold" rating from MarketBeat with a $2.00 target price.
Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026
Accuray Incorporated (NASDAQ: ARAY) announced it will report its third quarter fiscal year 2026 financial results on May 6, 2026. A conference call will be hosted by company management, with dial-in numbers and a live webcast available for investors and interested parties. The company is committed to advancing radiation therapy for various medical conditions.
Accuray schedules May 6 call for fiscal third-quarter results
Accuray (NASDAQ: ARAY) will report its Q3 fiscal 2026 financial results on May 6, 2026, for the period ending March 31, 2026. The company will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, with replay options available for interested investors. This announcement follows recent efforts by Accuray to implement a transformation plan aimed at improving operating profitability, despite reporting declining revenues in previous quarters.
How many employees work at Accuray?
Accuray, Inc. currently employs 1,028 individuals, according to Revelio Labs data updated in December 2025. The company has experienced a YoY growth rate of -10.2% in employee count. Historical data shows fluctuating employee numbers and active job postings over recent years.
